(+/-)-3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetate | 1033608-25-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: (+/-)-3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetate
• 英文别名: 3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetic acid；3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetate salt；3'-aminospiro[1H-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[c]pyridine]-2-one;2,2,2-trifluoroacetic acid
• CAS: 1033608-25-1
• 化学式: C₂HF₃O₂*C₁₄H₁₂N₄O
• 分子量: 366.299
• InChiKey: YNCKBDLEAGYPSF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.68
• 重原子数：
  26
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  118
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  lithium (2a-methyl-4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)acetate 、 (+/-)-3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetate 在 chloro-N,N,N',N'-bis(tetramethylene)formamidinium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 2-(2a-methyl-4-oxo-2a,3,4,5-tetrahydropyrrolo[4,3,2-de]quinolin-1(2H)-yl)-N-(2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-3-yl)acetamide
  参考文献：
  名称：

  WO2008/153852

  摘要：

  公开号：
• 作为产物：
  描述：

  (+/-)-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxylic acid 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 生成 (+/-)-3-amino-5,7-dihydrospiro[cyclopenta[c]pyridine-6,3'-pyrrolo[2,3-b]pyridin]-2'(1'H)-one trifluoroacetate
  参考文献：
  名称：

  WO2008/153852

  摘要：

  公开号：

文献信息

• BICYCLIC ANILIDE HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20100093759A1

  公开（公告）日：2010-04-15

  Compounds of formula I: I (wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  公式I的化合物：I（其中变量A1、A2、B、m、n、J、R4、G1、G2、G3和Y如本文所述），它们是CGRP受体拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• CONSTRAINED SPIROCYCLIC COMPOUNDS AS CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20100069359A1

  公开（公告）日：2010-03-18

  Compounds of formula I: (wherein variables A 1 , A 2 , A 3 , G 1 , G 2 , G 3 , J, m, n, p, R 1 , R 2 , R 3 , R 4 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式(I)的化合物：（其中变量A1、A2、A3、G1、G2、G3、J、m、n、p、R1、R2、R3、R4和Y如本文所述），它们是CGRP受体的拮抗剂，可用于治疗或预防CGRP参与的疾病，如偏头痛。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的疾病中使用这些化合物和组合物的用途。
• Constrained spirocyclic compounds as CGRP receptor antagonists
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07951795B2

  公开（公告）日：2011-05-31

  Compounds of formula I: (wherein variables A1, A2, A3, G1, G2, G3, J, m, n, p, R1, R2, R3, R4 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  式I的化合物：（其中变量A1、A2、A3、G1、G2、G3、J、m、n、p、R1、R2、R3、R4和Y如本文所述），它们是CGRP受体拮抗剂，并且在治疗或预防CGRP参与的疾病，如偏头痛方面是有用的。本发明还涉及包含这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病方面使用这些化合物和组合物。
• ARYL HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
  申请人：Bell Ian M.

  公开号：US20100120809A1

  公开（公告）日：2010-05-13

  Compounds of formula I: (wherein variables A 1 , A 2 , B, m, n, J, X, R 4 , G 1 , G 2 , G 3 and Y are as described herein) which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物I的公式为：（其中变量A1，A2，B，m，n，J，X，R4，G1，G2，G3和Y如本文所述），它们是CGRP受体的拮抗剂，可用于治疗或预防CGRP参与的疾病，例如偏头痛。本发明还涉及包括这些化合物的制药组合物以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物。
• Tricyclic anilide heterocyclic CGRP receptor antagonists
  申请人：Merck, Sharp & Dohme Corp.

  公开号：US08163752B2

  公开（公告）日：2012-04-24

  Compounds of formula I: wherein variables A1, A2, B, m, n, J, R4, G1, G2, G3 and Y are as described herein, which are antagonists of CGRP receptors and which are useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

  化合物的公式为I：其中变量A1、A2、B、m、n、J、R4、G1、G2、G3和Y如本文所述，这些化合物是CGRP受体拮抗剂，并且对于治疗或预防CGRP参与的疾病（如偏头痛）是有用的。本发明还涉及包括这些化合物的制药组合物，以及在预防或治疗CGRP参与的这些疾病中使用这些化合物和组合物的用途。